ABBV · 10-Q · 2026Q2 · Full report

U.S. Manufacturing Investment

AbbVie Inc. · 2026-08-03 · Importance 9 · Surprise 42 · Contradicted

AbbVie announced a pharmaceutical manufacturing campus in North Carolina incorporating advanced manufacturing, laboratory technologies, and artificial intelligence. The company also announced two new manufacturing facilities in Illinois for next-generation neuroscience and obesity medications. AbbVie agreed to acquire a device manufacturing facility in Arizona, and the transaction closed in July 2026. These projects form part of AbbVie’s stated plan to invest in U.S. research, development, manufacturing, and capacity, including a pledged $100 billion over the next decade.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
assetspositivecommitted+62.9%AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade…
cashnegativecommitted-62.9%AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade…
assetspositiveprobableAbbVie announced an investment to build a pharmaceutical manufacturing campus in North Carolina in 2026 to support production of…
cashnegativeprobableAbbVie announced an investment to build a pharmaceutical manufacturing campus in North Carolina in 2026 to support production of…
assetspositiveprobableAbbVie announced investments to add two new manufacturing facilities in Illinois in 2026 to support next generation neuroscience and…
cashnegativeprobableAbbVie announced investments to add two new manufacturing facilities in Illinois in 2026 to support next generation neuroscience and…